Quantcast

1 in 3 Canadians with Rheumatoid Arthritis (RA) Don’t Respond To Current Treatment

June 4, 2014

New oral XELJANZ( TM), now available in Canada

KIRKLAND, QC, June 4, 2014 /CNW/ – Catherine Hofstetter was diagnosed
with rheumatoid arthritis 22 years ago and it changed her life. “My
diagnosis felt like a life sentence,” says Hofstetter. “Even though I
was able to find a treatment to help me manage my symptoms, small,
everyday things like buttoning a shirt can still be difficult. New
treatments are essential in bringing hope to patients that their
disease can be managed.”

Although multiple treatments for RA exist, there remains an unmet need
for Canadians living with this serious autoimmune disease.(1) Not everyone with RA responds to currently available treatments.(2) But Canadians with RA now have a new oral treatment option with the
approval of XELJANZ (tofacitinib citrate) by Health Canada.

“Up to one-third of people with RA are not adequately responding to
current treatments and about half stop responding to a particular agent
within five years,” said Dr. William Bensen, Clinical Professor,
McMaster University, Rheumatologist, St. Joseph’s Hospital, Hamilton.
“XELJANZ is a new oral option for Canadians living with this
debilitating and chronic disease. Its mechanism of action targets the
inflammation associated with rheumatoid arthritis from inside the
cell.”

XELJANZ: A NEW ORAL OPTION

XELJANZ is the first RA treatment in a new class of drugs known as Janus
kinase (JAK) inhibitors, which are signaling pathways inside the cell
that play an important role in the inflammation involved in this
progressive disease.(3)

XELJANZ 5 mg twice daily in combination with methotrexate (MTX) is
indicated for reducing the signs and symptoms of RA, in adult patients
with moderately to severely active RA, who have had an inadequate
response to MTX. In cases of intolerance to MTX, physicians may
consider the use of XELJANZ alone.(4)

“Rheumatoid arthritis is a leading cause of disability in Canada.(5) It brings with it a burden of pain that those living with the disease
must face daily,” said Joanne Simons, Chief Mission Officer, The
Arthritis Society. “The availability of new medicines is a positive
step forward for Canadians who suffer from rheumatoid arthritis.”

The XELJANZ bottle cap has also been awarded The Arthritis Society’s
ease-of-use commendation, which recognizes the importance of helping
make life easier for people who have arthritis and other physical
limitations.

“Given Pfizer Canada’s long heritage in the area of arthritis and
rheumatology, we understand that the experiences and challenges for
each person suffering from RA are unique,” said Dr. Vratislav Hadrava,
Chief Medical Officer, Pfizer Canada Inc. “The approval of XELJANZ
gives Canadian physicians a new option to help address these
challenges. We are also pleased that we can provide arthritis-friendly
packaging for XELJANZ.”

XELJANZ was originally discovered in Pfizer labs in Groton, Connecticut
and over the course of 20 years Pfizer invested more than $1 billion
into the discovery, development and commercialization of XELJANZ.

XELJANZ has been evaluated in approximately 4,800 patients yielding
7,000 patient-years of exposure in a comprehensive, global clinical
development program that included five pivotal Phase 3 trials and two
ongoing long-term extension studies in 45 countries. This large
international clinical development program includes sites across Canada
(including Quebec).

THE FACTS: RHEUMATOID ARTHRITIS IN CANADA(5)

        --  About one out of every 100 Canadians has rheumatoid arthritis
            (RA). That's approximately 300,000 Canadians.
        --  Anyone can get RA at any age, but it most often appears between
            the ages of 25 and 50.
        --  RA affects women three times more often than men.
        --  There remains an unmet medical need for additional therapeutic
            options with proven efficacy and acceptable safety profiles in
            patients with rheumatoid arthritis.
        --  RA can cause permanent joint damage quickly when it is not
            treated and controlled.
        --  Treating RA early and aggressively can improve the long-term
            outcome and significantly reduce damage.

ABOUT PFIZER CANADA INC.

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the
world’s leading biopharmaceutical companies. Our diversified health
care portfolio includes some of the world’s best known and most
prescribed medicines and vaccines. Historically, Pfizer Inc. has
invested more than US$7 billion toward developing safe and effective
medicines. At Pfizer, we’re working together for a healthier world. To
learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/Pfizer.Canada).

REFERENCES

________________________________

(1) FDA Advisory Committee Briefing Document. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdf. Last accessed May 21, 2014. (BD pg. 19)

(2) Bykerk V. Unmet needs in rheumatoid arthritis. Journal of Rheumatology. 2009; 82; 42-46

(3) Understanding Rheumatoid Arthritis and the JAK Pathways. Science
Writers’ Guide.

(4) XELJANZ Product Monograph, Pfizer Canada Inc., April 2014

(5) The Arthritis Society. Rheumatoid Arthritis. http://www.arthritis.ca/page.aspx?pid=982. Accessed May 22, 2014.

SOURCE Pfizer Canada Inc.


Source: PR Newswire



comments powered by Disqus